1. Home
  2. IHD vs SKYE Comparison

IHD vs SKYE Comparison

Compare IHD & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IHD
  • SKYE
  • Stock Information
  • Founded
  • IHD 2011
  • SKYE 2012
  • Country
  • IHD United States
  • SKYE United States
  • Employees
  • IHD N/A
  • SKYE N/A
  • Industry
  • IHD Investment Managers
  • SKYE Biotechnology: Pharmaceutical Preparations
  • Sector
  • IHD Finance
  • SKYE Health Care
  • Exchange
  • IHD Nasdaq
  • SKYE Nasdaq
  • Market Cap
  • IHD 89.7M
  • SKYE 80.7M
  • IPO Year
  • IHD N/A
  • SKYE N/A
  • Fundamental
  • Price
  • IHD $5.20
  • SKYE $3.14
  • Analyst Decision
  • IHD
  • SKYE Buy
  • Analyst Count
  • IHD 0
  • SKYE 6
  • Target Price
  • IHD N/A
  • SKYE $18.67
  • AVG Volume (30 Days)
  • IHD 27.7K
  • SKYE 178.7K
  • Earning Date
  • IHD 01-01-0001
  • SKYE 02-18-2025
  • Dividend Yield
  • IHD 10.32%
  • SKYE N/A
  • EPS Growth
  • IHD N/A
  • SKYE N/A
  • EPS
  • IHD N/A
  • SKYE N/A
  • Revenue
  • IHD N/A
  • SKYE N/A
  • Revenue This Year
  • IHD N/A
  • SKYE N/A
  • Revenue Next Year
  • IHD N/A
  • SKYE N/A
  • P/E Ratio
  • IHD N/A
  • SKYE N/A
  • Revenue Growth
  • IHD N/A
  • SKYE N/A
  • 52 Week Low
  • IHD $4.49
  • SKYE $2.31
  • 52 Week High
  • IHD $5.47
  • SKYE $19.41
  • Technical
  • Relative Strength Index (RSI)
  • IHD 55.82
  • SKYE 52.82
  • Support Level
  • IHD $5.11
  • SKYE $2.70
  • Resistance Level
  • IHD $5.25
  • SKYE $3.29
  • Average True Range (ATR)
  • IHD 0.06
  • SKYE 0.45
  • MACD
  • IHD 0.01
  • SKYE 0.05
  • Stochastic Oscillator
  • IHD 73.68
  • SKYE 41.27

About IHD Voya Emerging Markets High Income Dividend Equity Fund

Voya Emerging Markets High Dividend Equity Fund is a diversified closed-end management investment company. Its primary investment objective is to provide total return through a combination of current income, capital gains, and capital appreciation. The company seeks to achieve its investment objectives by investing principally in a portfolio of equity securities, and issuers in emerging market countries. The Fund will also normally seek to secure gains and enhance the stability of returns over a market cycle by writing (selling) call options on selected exchange-traded funds (ETFs) and/or international, regional, or country indices of equity securities, and/or on equity securities.

About SKYE Skye Bioscience Inc. Common Stock

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: